Physical inactivity increases the risk for all-cause and cardiovascular mortality by 30% to 40% in the general population[@bib1] and is considered as an independent risk factor for heart failure (HF).[@bib2] Conversely, habitual physical activity, that is, daily walking performance, as objectively evaluated by an accelerometer, is an important determinant of functional capacity in patients with chronic HF.[@bib3] Furthermore, increased physical activity in the form of a structured exercise intervention improves exercise tolerance and quality of life (QoL) in HF[@bib4] and heart transplantation (HT) patients,[@bib5] but limited number of studies evaluated its impact in patients implanted with a left ventricular assist device (LVAD).[@bib6; @bib7] Before critically evaluating exercise as a potential therapy for patients on LVAD support, it is important to understand the pattern of habitual, daily physical activity and its relation to QoL. Consequently, the aim of this study was to define the short- and long-term effects of LVAD implantation and HT on everyday physical activity, energy expenditure, and QoL.

Methods {#sec1}
=======

A prospective, observational, repeated-measures design was chosen to characterize changes over time that occur in physical activity and QoL in patients on LVAD support and HT patients. The setting for the study was an inpatient HT assessment. Based on the assessment, patients were listed for HT, if judged to be too unwell to wait for a transplant, or an LVAD was implanted, if they would become better transplant candidates after a period of LVAD support. Those too well for transplant were continued on optimal medical management. These 3 scenarios were the basis of the 3 patients groups: LVAD, HT, and HF. HF patients had not received LVAD or HT during the study. Changes in physical activity and QoL of 12 HT patients were compared with those of 14 LVAD and 14 HF patients. Physical activity--related subgroup comparisons were performed with age-, gender-, and body mass index--matched 14 HF patients and 14 healthy subjects. In LVAD and HT patients, data on physical activity and QoL were collected at 4 different time points: baseline assessment, that is, 4 to 6 weeks after surgery and after discharge from hospital and then follow-up assessments at 3, 6, and 12 months after surgery. The data on patients with HF were collected at baseline and at 12 months, and on the healthy subjects data were only collected at 1 time point. Both LVAD and HT patients completed in-hospital postsurgery mobility and rehabilitation program guided by a physiotherapist. The study protocol was approved by the County Durham and Tees Valley Research and Ethics Committee. All participants gave written informed consent. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

All patients undergoing LVAD implantation (HeartWare, HeartWare International Inc., Framingham, Massachusetts) or HT who met study inclusion criteria were recruited into the study from September 2010 to June 2013 at the Freeman Hospital, Newcastle upon Tyne, United Kingdom. Their baseline physical activity and QoL data were compared with those of 14 patients with chronic HF who were assessed but not listed for HT and 14 healthy participants. Subjects\' demographic and clinical characteristics are presented in [Table 1](#tbl1){ref-type="table"}. The study inclusion criteria included age from 18 to 60 years, sufficient English language skills to answer the questionnaires, completion of follow-up visits, and willingness to participate. Study exclusion criteria included physical condition limiting rehabilitation or mobility such as stroke; myopathy; neuropathy; renal, pulmonary, or hepatic dysfunction; or active uncontrolled infection. Written informed consent was received from all subjects enrolled in the study.

Patients on LVAD support were treated with warfarin for a target international normalized ratio of 2.7 and antiplatelets as well as with angiotensin-converting enzyme inhibitors, β blockers, aldosterone antagonists, angiotensin receptor blockers, and diuretics as appropriate. HT patients received triple-drug immunosuppressive maintenance therapy, usually including a calcineurin inhibitor, prednisolone, and azathioprine. Patients with chronic HF were treated with β blockers (n = 14), angiotensin-converting enzyme inhibitors (n = 10), aldosterone antagonists (n = 6), diuretics (n = 12), statins (n = 8), angiotensin receptor blockers (n = 5), anticoagulants (n = 9), antiarrhythmics (n = 5), and digoxin (n = 3).

Habitual physical activity was objectively evaluated using a validated portable multisensor array (SenseWear Pro3, BodyMedia Inc., Pennsylvania).[@bib8] The monitor was worn for 7 days and was only removed for bathing. The multisensor array measures 4 key metrics: skin temperature, galvanic skin response, heat flux, and motion by way of a 3-axis accelerometer. The sensors, combined with algorithms, calculate the average daily energy expenditure relative to baseline metabolism (metabolic equivalent: MET per day \[1 MET = resting metabolic rate\]), total energy expenditure (calories per day), active energy expenditure (total calories expended over 3 METs per day), physical activity duration (minutes \>3 METs per day), average daily number of steps walked, sedentary activity (minutes \<3 METs per day), moderate activity (minutes between 3 and 6 METs per day), vigorous activity (minutes between 6 and 9 METs day), and very vigorous activity (minutes \>6 METs day).[@bib8; @bib9] HF-related QoL was assessed with the Minnesota Living with Heart Failure (MLHF) Questionnaire.[@bib10]

All statistical analyses were carried out using SPSS, version 19.0 (SPSS Inc., Chicago, Illinois). Before statistical analysis, data were checked for univariate and multivariate outliers using standard z-distribution cutoffs and Mahalanobis distance tests. Normality of distribution was assessed using a Kolmogorov-Smirnov test. Analysis of variance was used to test differences in physical activity and QoL among LVAD, HT, and HF patients and healthy controls as well as to evaluate changes at different time points in LVAD and HT patients. To identify groups that differed significantly from one another, a post hoc Tukey test was performed. The relation between QoL and physical activity in the patients was evaluated using the Pearson coefficient of correlation. Statistical significance was indicated if p \<0.05. All data are presented as mean ± SEM unless otherwise indicated.

Results {#sec2}
=======

The total number of patients screened for the study was 52 (18 LVAD, 14 HT, and 20 HF). Study participants\' demographic and clinical characteristics are described in [Table 1](#tbl1){ref-type="table"}. The groups were not randomly assigned, and the treatment was based on the outcome of the transplant assessment. No significant differences were found in age and body mass index among LVAD, HT, HF, and healthy subjects. During the follow-up study, 2 patients in the LVAD group died and 2 refused to complete the study. There were 8 hospitalizations in 7 patients in the LVAD group for infections, 2 hospitalizations for arrhythmias, 1 with HF, 1 anemia, 1 with a transient ischemic attack, 1 with a possible deep vein thrombosis, and 1 with light-headedness. Of the heart transplant patients, 3 patients had admissions for infections and 1 patient had 3 admissions for rejection. Of the 20 patients with HF who were initially screened, 4 refused to take part in the study, 2 received HT, and 10 of remaining 14 patients completed investigation at 12 months after the baseline assessment.

Baseline physical activity measures demonstrated that patients in the LVAD and HT groups expended 25% (716 kcal) and 22% (640 kcal) less energy per day, respectively, in comparison with healthy subjects (p \<0.05). Similarly, patients with HF expended 27% (772 kcal) less energy per day than healthy subjects ([Table 2](#tbl2){ref-type="table"}). Daily physical activity (i.e., number of steps) was significantly reduced in the 3 patient groups with LVAD and HT patients at baseline performing only 15% and 28% and HF 51% of that of healthy subjects ([Table 2](#tbl2){ref-type="table"}). At baseline, duration of physical activity (i.e., \>3 METs) was significantly reduced in LVAD patients compared with both HT and HF patients ([Table 2](#tbl2){ref-type="table"}). LVAD and HT patients showed active energy expenditure that was significantly lower than that of healthy subjects ([Table 2](#tbl2){ref-type="table"}). Moderate physical activity, that is, 3 to 6 METs, was a major contributor to active energy expenditure in all 4 groups. Vigorous physical activity was identified in healthy and HT participants but not in LVAD and HF patients ([Table 2](#tbl2){ref-type="table"}). The MLHF QoL score was not significantly different among the 3 groups of patients at baseline ([Table 2](#tbl2){ref-type="table"}).

During the follow-up period there were no significant changes in body mass during 12 months after LVAD implantation or HT. The body mass was also not changed in patients with HF. Total daily energy expenditure increased significantly from baseline to 3 months in LVAD patients (p \<0.05) but remained unchanged from 3 to 12 months after the surgery. In contrast, HT patients demonstrated significantly higher total energy expenditure at 12 months ([Table 3](#tbl3){ref-type="table"}). Daily number of steps significantly increased by 60% and 52% from baseline to 3 months in LVAD and HT patients, respectively. It remained, however, unchanged from 3 to 12 months and significantly lower than that of healthy subjects ([Figure 1](#fig1){ref-type="fig"}). This was further associated with significant increase in physical activity duration and active energy expenditure ([Figure 1](#fig1){ref-type="fig"}). MLHF scores decreased over time from baseline in both LVAD and HT patients indicating an improvement in QoL ([Table 3](#tbl3){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). In contrast with LVAD and HT patients, those with HF had decreased daily number of steps, activity duration, and active energy expenditure at 12 months from baseline and increased MLHF scores ([Figure 1](#fig1){ref-type="fig"}).

At any time point during the 12-month follow-up, LVAD patients demonstrated significantly lower number of steps, physical activity duration, and active energy expenditure in comparison with HT patients ([Figure 1](#fig1){ref-type="fig"}). HT patients at 12 months after surgery demonstrated average daily physical activity duration that was only 7% below healthy controls (119 vs 128 min/day) and reached 80% active energy of controls (602 vs 751 kcal/day). The QoL score was significantly lower in HT than in LVAD patients at 3, 6, and 12 months after surgery ([Figure 1](#fig1){ref-type="fig"}).

Discussion {#sec3}
==========

To our knowledge, this is the first study to report physical activity in patients after LVAD implantation and HT. There are 3 major findings. First, within the first 4 to 6 weeks after surgery, LVAD and HT patients demonstrated low physical activity levels accompanied with low energy expenditure and increased sedentary time. Second, from baseline to 3 months there was a significant increase in physical activity--associated measures and improvement in QoL in both LVAD and HT, but the number of steps remained unchanged from 3 to 12 months after surgery. Finally, HT patients demonstrate higher activity level and better QoL than LVAD patients during the 12-month follow-up. In contrast with HT and LVAD patients, those with HF demonstrated a decrease in physical activity--associated measures at 12 months compared with baseline.

The HT and particularly LVAD patients showed low activity levels on hospital discharge. Although both LVAD and HT patients completed in-hospital postsurgery mobility and rehabilitation program, they remained inactive. Strong association between daily walking performance and functional capacity in HF has been reported.[@bib3] It is therefore not surprising that LVAD and HT patients a few weeks after surgery demonstrate only ∼40% and ∼50% of maximal predicted functional capacity, respectively.[@bib11; @bib12] Inactivity, low energy expenditure, and diminished functional performance early after the surgery are likely to be due to a high incidence of psychological distress and deconditioning found in LVAD and HT patients early after the surgery.[@bib11; @bib13]

In comparison with baseline, there was a significant improvement in physical activity--associated measures and QoL at 3 months after surgery in both LVAD and HT patients. That QoL and functional capacity improve on hospital discharge during longitudinal follow-up of LVAD and HT patients has been previously reported.[@bib12; @bib14; @bib15] It is, however, noticeable that increased daily activity level at 3 months in LVAD and HT patients, found in the present study, is markedly below healthy controls and in case of HT patients similar to that of HF patients. It should further be noted that QoL improved from baseline to 3 months by 24 and 33 points for LVAD and HT patients, respectively. This is important, as a 5-point change in the MLHF score has been previously determined to be clinically meaningful.[@bib10] Further comparison between the different patient groups reveals that 3 months after surgery, LVAD and HT patients show better QoL than patients with HF. QoL was not changed from 3 to 12 months in LVAD patients, likely because of frequent hospitalization. Our findings further suggest that patients\' body mass remained unchanged over time. This is particularly interesting for LVAD patients and contrasts findings from a recent large retrospective study that suggests a significant increase in body mass after a continuous LVAD implantation.[@bib16] The limited number of patients recruited in the present study may limit generalization of our findings.

Our data further suggest that daily number of steps and QoL remained unchanged at 3, 6, and 12 months after surgery for LVAD, but the QoL was further improved at 6 months in HT patients. This is surprising, as a significant improvement in functional capacity has been reported several months after HT and LVAD implantation allowing patients to independently perform activities of daily living.[@bib12; @bib17; @bib18] In agreement with our findings, previous studies also showed that health-related QoL improved from baseline to 3 months after surgery and remained unchanged during 1-year follow-up.[@bib14; @bib19]

Finally, our results suggest that, not only at baseline but also at 3, 6, and 12 months after surgery, HT patients demonstrate higher levels of physical activity and better QoL than LVAD patients. These findings are in line with previous studies suggesting greater functional capacity of HT compared with LVAD patients.[@bib7; @bib11; @bib12; @bib20] In contrast with LVAD patients who showed a plateauing during the follow-up, HT patients at 12 months demonstrated physical activity duration and active energy expenditure that were 93% and 80% of healthy controls, respectively. This is an interesting finding considering that the number of steps remained unchanged from 3 to 12 months. A plausible explanation for such finding is that from 3 to 6 months the intensity of the activity was mostly \<3 METs (characterized as sedentary activity), whereas at 12 months moderate activity (3 to 6 METs) was predominantly detected, resulting in a significant increase in activity duration and active energy expenditure. It has further been suggested that vigorous intensity appears to convey greater cardiovascular and functional benefits than exercise of a moderate intensity.[@bib21] Considering that HT and LVAD are different treatment methods, the optimal physical activity and exercise interventions to improve outcomes in these patients remain to be determined in large clinical trials. Therefore, general recommendations for exercise therapy in HT and LVAD patients need to be considered with caution and are likely to differentiate in volume and intensity from those of general cardiology patients.

The present study is not without limitations. First, the lack of presurgical activity monitoring prevents our understanding of individual variation in daily activity level between HT and LVAD implantation candidates. Second, small sample size limits the generalizability of our findings. Finally, the study may be biased by the fact that predominantly male patients were available for this analysis, particularly in LVAD group.
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![Longitudinal changes in the daily number of steps *(A)*, physical activity duration *(B)*, active energy expenditure *(C)*, and QoL *(D)*. Healthy data is a single reference data point and not a longitudinal series of data. ^∗^p \<0.05, HT versus LVAD; ^†^p \<0.05, HF versus LVAD; ^‡^p \<0.05, HF versus HT.](gr1){#fig1}

###### 

Subject demographic and clinical characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Patients Characteristics            LVAD\       HT\           HF\          Healthy\            ANOVA\
                                      (n = 14)    (n = 12)      (n = 14)     Subjects (n = 14)   p Value
  ----------------------------------- ----------- ------------- ------------ ------------------- ----------------------------------------------
  Age (years)                         49 ± 14     48 ± 17       46 ± 10      48 ± 14             0.959

  Men (%)                             100         70            67           71                  ---

  Weight (kg)                         85 ± 16     77 ± 11       80 ± 15      84 ± 17             0.617

  Height (cm)                         177 ± 10    170 ± 8       169 ± 9      174 ± 13            0.081

  Body mass index (kg/m^2^)           27 ± 6      27 ± 6        29 ± 5       27 ± 4              0.725

  Etiology of heart failure                                                                      

  Idiopathic dilated cardiomyopathy   5           6             11           N/A                 ---

  Ischemic cardiomyopathy             9           2             3            N/A                 ---

  Other                               ---         4             ---          N/A                 ---

  LVEF (%)                            13 ± 2      14 ± 6        18 ± 3       64 ± 8              0.004[∗](#tbl1fnlowast){ref-type="table-fn"}

  NYHA class                          3.7 ± 0.2   3.8 ± 0.3     3.3 ± 0.5    ---                 

  Cardiac index (l/min/m^2^)          1.7 ± 0.4   1.8 ± 0.3 4   2.1 ± 0.4    3.6 ± 0.7           0.002[∗](#tbl1fnlowast){ref-type="table-fn"}

  Peak O~2~ consumption (ml/kg/min)   9.9 ± 2.1   10.2 ± 2.3    14.6 ± 2.8   34.6 ± 9.2          

  INTERMACS score                     2.8 ± 0.9   ---           ---          ---                 ---
  ---------------------------------------------------------------------------------------------------------------------------------------------

Other includes tricuspid atresia (×2) and restrictive cardiomyopathy (×2).

ANOVA = analysis of variance; HF = heart failure; HT = heart transplantation; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association functional class.

Healthy versus LVAD, HT, and chronic heart failure (p \<0.01).

###### 

Energy expenditure, physical activity and quality of life at baseline

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                   LVAD          HT            HF            Healthy\       ANOVA\
                                                                                        Subjects       p Value
  ------------------------------------------- ------------- ------------- ------------- -------------- ----------------------------------------------------------------------------------------
  Total energy expenditure (kcal/day)         2164 ± 112    2240 ± 163    2108 ± 211    2880 ± 153     0.004[∗](#tbl2fnlowast){ref-type="table-fn"}

  Steps (per day)                             1603 ± 302    3036 ± 439    5490 ± 1058   10,756 ± 568   \<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}[†](#tbl2fndagger){ref-type="table-fn"}

  Average METs (kcal/kg/hour)                 1.07 ± 0.06   1.28 ± 0.08   1.23 ± 0.06   1.45 ± 0.04    \<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}[‡](#tbl2fnddagger){ref-type="table-fn"}

  Active energy expenditure (kcal/day)        78 ± 30       330 ± 129     313 ± 95      751 ± 77       \<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}[‡](#tbl2fnddagger){ref-type="table-fn"}

  Physical activity duration (min/day)        18 ± 8        69 ± 22       65 ± 18       128 ± 10       \<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}[‡](#tbl2fnddagger){ref-type="table-fn"}

  Sedentary time (min/day)                    1410 ± 10     1303 ± 32     1322 ± 24     1261 ± 17      \<0.001[‡](#tbl2fnddagger){ref-type="table-fn"}

  Moderate physical activity (min/day)        18 ± 8        66 ± 25       64 ± 18       120 ± 9        \<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}[‡](#tbl2fnddagger){ref-type="table-fn"}

  Vigorous physical activity (min/day)        0 ± 0         3.5 ± 2.3     0.5 ± 0.3     5.9 ± 1.7      0.014[§](#tbl2fnsection){ref-type="table-fn"}

  Very vigorous physical activity (min/day)   0 ± 0         0.1 ± 0.3     0 ± 0         1.6 ± 1.5      0.489

  MLHF quality of life                        81 ± 5        72 ± 8        74 ± 4        N/A            0.445
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANOVA = analysis of variance; HF = heart failure; HT = heart transplantation; LVAD = left ventricular assist device; METs = metabolic equivalent units; MLHF = Minnesota Living with Heart Failure Questionnaire; N/A = not applicable.

Healthy versus LVAD, HT, and HF (p \<0.05).

LVAD versus HF (p \<0.05).

LVAD versus HF, HT, and healthy (p \<0.05).

Healthy and HT versus HF and LVAD (p \<0.05).

###### 

Longitudinal changes in energy expenditure, physical activity, and quality of life

  Variables                                   Patient Group                                         Baseline                                          3 Months                                              6 Months                                                                                                                      12 Months
  ------------------------------------------- ----------------------------------------------------- ------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Weight (kg)                                 LVAD                                                  86 ± 17                                           86 ± 16                                               89 ± 16                                                                                                                       83 ± 11
  HT                                          76 ± 15                                               78 ± 14                                           77 ± 15                                               80 ± 17                                                                                                                       
  HF                                          81 ± 17                                               ---                                               ---                                                   82 ± 16                                                                                                                       
  Steps (per day)                             LVAD                                                  1603 ± 302                                        3712 ± 807                                            4007 ± 1084                                                                                                                   3997 ± 956[∗](#tbl3fnlowast){ref-type="table-fn"}
  HT                                          3036 ± 439                                            6265 ± 443                                        6563 ± 824                                            6288 ± 701[∗](#tbl3fnlowast){ref-type="table-fn"}                                                                             
  HF                                          5490 ± 1058                                           ---                                               ---                                                   3560 ± 885[∗](#tbl3fnlowast){ref-type="table-fn"}[†](#tbl3fndagger){ref-type="table-fn"}                                      
  Total energy expenditure (kcal/day)         LVAD                                                  2164 ± 112                                        2392 ± 105                                            2398 ± 108                                                                                                                    2421 ± 117[∗](#tbl3fnlowast){ref-type="table-fn"}
  HT                                          2240 ± 163                                            2406 ± 137                                        2443 ± 148                                            3572 ± 202[∗](#tbl3fnlowast){ref-type="table-fn"}[‡](#tbl3fnddagger){ref-type="table-fn"}                                     
  HF                                          2108 ± 211                                            ---                                               ---                                                   1989 ± 198[†](#tbl3fndagger){ref-type="table-fn"}                                                                             
  Average METs (kcal/kg/hour)                 LVAD                                                  1.07 ± 0.06                                       1.18 ± 0.07                                           1.19 ± 0.08                                                                                                                   1.20 ± 0.09
  HT                                          1.28 ± 0.08[‡](#tbl3fnddagger){ref-type="table-fn"}   1.31 ± 0.05                                       1.35 ± 0.07[‡](#tbl3fnddagger){ref-type="table-fn"}   1.39 ± 0.06[‡](#tbl3fnddagger){ref-type="table-fn"}                                                                           
  HF                                          1.23 ± 0.06                                           ---                                               ---                                                   1.14 ± 0.05[†](#tbl3fndagger){ref-type="table-fn"}                                                                            
  Sedentary time (min/day)                    LVAD                                                  1410 ± 10                                         1353 ± 26                                             1293 ± 52                                                                                                                     1280 ± 62
  HT                                          1303 ± 32                                             1308 ± 21                                         1329 ± 18                                             1260 ± 29                                                                                                                     
  HF                                          1322 ± 24                                             ---                                               ---                                                   1388 ± 21[†](#tbl3fndagger){ref-type="table-fn"}                                                                              
  Moderate physical activity (min/day)        LVAD                                                  18 ± 8                                            48 ± 17                                               55 ± 16                                                                                                                       51 ± 20[∗](#tbl3fnlowast){ref-type="table-fn"}
  HT                                          66 ± 22[‡](#tbl3fnddagger){ref-type="table-fn"}       86 ± 46[‡](#tbl3fnddagger){ref-type="table-fn"}   84 ± 14[‡](#tbl3fnddagger){ref-type="table-fn"}       144 ± 22[§](#tbl3fnsection){ref-type="table-fn"}[‡](#tbl3fnddagger){ref-type="table-fn"}                                      
  HF                                          64 ± 18                                               ---                                               ---                                                   41 ± 12[∗](#tbl3fnlowast){ref-type="table-fn"}[†](#tbl3fndagger){ref-type="table-fn"}                                         
  Vigorous physical activity (min/day)        LVAD                                                  0 ± 0                                             1.3 ± 0.7                                             2.4 ± 1.9                                                                                                                     0.5 ± 0.3
  HT                                          3.5 ± 2.3                                             2.3 ± 1.3                                         2.9 ± 1.5                                             4.3 ± 2.3                                                                                                                     
  HF                                          0.5 ± 0.3                                             ---                                               ---                                                   0 ± 0                                                                                                                         
  Very vigorous physical activity (min/day)   LVAD                                                  0 ± 0                                             0 ± 0                                                 0 ± 0                                                                                                                         0 ± 0
  HT                                          0 ± 0                                                 0 ± 0                                             0 ± 0                                                 0 ± 0                                                                                                                         
  HF                                          0 ± 0                                                 ---                                               ---                                                   0 ± 0                                                                                                                         
  MLHF quality of life                        LVAD                                                  81 ± 5                                            57 ± 7                                                63 ± 7                                                                                                                        60 ± 5[∗](#tbl3fnlowast){ref-type="table-fn"}
  HT                                          72 ± 8                                                39 ± 5[‡](#tbl3fnddagger){ref-type="table-fn"}    30 ± 6[‡](#tbl3fnddagger){ref-type="table-fn"}        29 ± 7[∗](#tbl3fnlowast){ref-type="table-fn"}[‡](#tbl3fnddagger){ref-type="table-fn"}                                         
  HF                                          74 ± 4                                                ---                                               ---                                                   82 ± 6[∗](#tbl3fnlowast){ref-type="table-fn"}[†](#tbl3fndagger){ref-type="table-fn"}[‖](#tbl3fnverbar){ref-type="table-fn"}   

p \<0.05, 12 months versus baseline.

p \<0.05, HF versus HT.

p \<0.05, HT versus LVAD.

p \<0.05, 12 months versus 3 and 6 months.

p \<0.05, HF versus LVAD.
